TITLE

Deferiprone approved for iron overload

AUTHOR(S)
Traynor, Kate
PUB. DATE
November 2011
SOURCE
American Journal of Health-System Pharmacy;11/15/2011, Vol. 68 Issue 22, p2106
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the Food and Drug Administration (FDA) has approved deferiprone, marketed as Ferriprox by ApoPharma Inc. of Toronto, for the treatment of transfusional iron overload in patients with thalassemia. It mentions that every patient’s absolute neutrophil count should be measured before starting deferiprone therapy and weekly during treatment. The article also discusses the recommended dosage and labeling details for the drug, and the adverse events observed.
ACCESSION #
67225177

 

Related Articles

  • Perampanel approved for epilepsy. Traynor, Kate // American Journal of Health-System Pharmacy;12/ 1/2012, Vol. 69 Issue 23, p2024 

    The article reports the announcement made by Eisai Company Ltd., on FDA's approval to the drug Perampanel oral tablets, as a supplemental therapy for partial seizures for epilepsy patients. It also discusses the labeling information, the recommended dosage and the adverse reactions associated...

  • FDA actions.  // Hospital Medicine Alert;Dec2012 Pharmacology Watch, p2 

    No abstract available.

  • FDA actions.  // Clinical Cardiology Alert;Mar2012 Pharmacology, p2 

    The article reports several FDA actions including prohibition of cephalosporins in cattle, swine and turkeys, approval of a once-weekly, extended-release formulation of exenatide in treatment of type 2 diabetes, and approval of vismodegib in treatment of adults advanced basal cell carcinoma.

  • FDA actions.  // Clinical Oncology Alert;Mar2012 Supplement 2, p2 

    The article reports several FDA actions including prohibition of cephalosporins in cattle, swine and turkeys, approval of a once-weekly, extended-release formulation of exenatide in treatment of type 2 diabetes, and approval of vismodegib in treatment of adults advanced basal cell carcinoma.

  • FDA actions. Elliott, William T. // Critical Care Alert;Mar2012 Supplement, p2 

    The article reports several FDA actions including prohibition of cephalosporins in cattle, swine and turkeys; approval of a once-weekly, extended-release formulation of exenatide in treatment of type 2 diabetes; and approval of vismodegib in treatment of adults advanced basal cell carcinoma.

  • FDA actions.  // Clinical Cardiology Alert;Dec2012 Pharmacology Watch, p2 

    The article informs that the FDA has approved a new drug, omacetaxine mepesuccinate, for the treatment of chronic myelogenous leukemia (CML) and perampanel, an adjunctive treatment for partial onset seizures in patients 12 years of age and older.

  • FDA actions. Elliott, William T. // Clinical Oncology Alert;Dec2012 Pharmacology Watch, Vol. 28, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) have approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.

  • Vonoprazan: First Global Approval. Garnock-Jones, Karly // Drugs;Mar2015, Vol. 75 Issue 4, p439 

    Vonoprazan (Takecab) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer,...

  • FDA actions. Elliott, William T. // Hospital Medicine Alert;Jun2013 Pharmacology Watch, p2 

    The article describes the US Food and Drug Administration (FDA) actions. The FDA has issued new labeling information for tamper-proof oxycodone (OxyContin) but has barred generic forms of the original formulation of oxycodone. The FDA has given its approval to a fixed combination of doxylamine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics